Catheter Precision, Inc. Completes Enrollment of 75 Patients in LockeT-II Study

Rhea-AI Summary

Catheter Precision (NYSE American:VTAK) has reached a significant milestone in its LockeT-II Study, enrolling 75 patients. The study, part of a three-phase clinical trial, is expected to conclude in October 2024. This Phase II trial compares LockeT to manual compression, the current standard of care, in a randomized study of up to 100 patients.

The study aims to further evaluate LockeT's safety and effectiveness, as well as potential benefits such as pain reduction and cost savings. The successful completion of Phase I in 2023 demonstrated LockeT's functionality and safety, leading to the product's roll-out in early 2024. Final data analysis from Phase II will be submitted for peer-reviewed publication.

Positive

• Enrollment of 75 patients in Phase II study, indicating progress in clinical trials
• Successful completion of Phase I in 2023, showing product functionality and safety
• Product roll-out initiated in the first half of 2024

Negative

• None.

Medical Research Analyst

Catheter Precision's completion of patient enrollment for the LockeT-II study marks a significant milestone in the development of their innovative medical device. As a Medical Research Analyst, I find several aspects of this news particularly noteworthy:

• The study's rapid progression from Phase I to Phase II, with Phase I completed in 2023 and Phase II enrollment now finished, indicates strong momentum in the research process.
• The randomized, comparative design of Phase II, pitting LockeT against manual compression, is a robust approach to evaluate the device's efficacy and potential benefits.
• The focus on safety, effectiveness, pain reduction and cost savings as key metrics suggests a comprehensive evaluation of the device's value proposition.

However, investors should note that while the enrollment completion is positive, the final data analysis won't be available until October 2024. This timeline, coupled with the subsequent peer-review process, means that any potential market impact from these results is still some months away.

The successful completion of Phase I without safety events is encouraging, but it's important to await the Phase II results for a more definitive assessment of LockeT's potential. If the device demonstrates significant advantages over manual compression, particularly in pain reduction and cost savings, it could position Catheter Precision favorably in the medical device market.

Investors should monitor for any interim updates and prepare for potential stock volatility around the October data release. The outcome of this study could significantly influence the company's market position and future revenue prospects in the cardiovascular medical device sector.

Financial Analyst

From a financial perspective, Catheter Precision's progress with the LockeT-II study carries several implications for investors:

• Market readiness: The initiation of product roll-out in the first half of 2024, concurrent with ongoing studies, suggests confidence in the product and potential early revenue generation.
• R&D efficiency: The timely progression through study phases indicates efficient use of research and development resources, which is important for a medical device company's financial health.
• Potential market expansion: If LockeT demonstrates superiority over manual compression, particularly in cost savings, it could drive adoption in healthcare settings, potentially expanding Catheter Precision's market share.

However, investors should consider several financial aspects:

• Cash burn rate: Clinical studies are expensive and the company may face increased expenses during this period. It's important to monitor the balance sheet and cash position in upcoming quarterly reports.
• Revenue timeline: While product roll-out has begun, significant revenue impact may not be seen until after the study concludes and results are published, likely extending into 2025.
• Regulatory considerations: The success of the LockeT-II study could influence regulatory approvals in various markets, potentially affecting the company's global expansion plans and long-term revenue projections.

Investors should closely watch for any updates on the company's cash position, burn rate and initial sales figures from the early product roll-out. The October 2024 data release will be a critical inflection point that could significantly impact the stock's performance and the company's financial outlook.

FORT MILL, SC / ACCESSWIRE / July 25, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a US based innovative medical device company, announced today that it has enrolled 75 patients in its Phase II LockeT Study, which is now expected to conclude in October 2024.

As previously disclosed, the three phases of the LockeT studies began in 2023 and are intended to show the product's safety and benefits. Phase I was completed in 2023 and showed that LockeT works for its intended purpose and that there were no safety events. Product roll-out began in the first half of 2024, while the Company continues Phase II of the product studies.

Phase II compares manual compression, the current standard of care, to LockeT, in a one-to-one randomized study planned to include up to 100 patients and is designed to provide further evaluation of its safety and effectiveness, as well as additional data such as potential pain reduction and cost savings benefits. Enrollment completion is expected in October 2024 when final data analysis will be available for later submission to a peer-reviewed publication.

About LockeT

Catheter Precision's LockeT is a suture retention device intended to assist in hemostasis after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA.

About Catheter Precision

Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.

Forward-Looking Statements

Statements in this press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as "believe," "anticipate," "may," "might," "can," "could," "continue," "depends," "expect," "expand," "forecast," "intend," "ongoing," "predict," "plan," "rely," "should," "will," "may," "seek," "would," "forward," or the negative and alternative word forms of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding company plans to achieve full enrollment of Phase II in October of 2024 and to complete Phase II by the end of fourth quarter, as well as our expectations for the availability and publication of data from Phase II, as well as its continuing pursuit of other studies and the gathering and publishing of additional clinical data for the company's two product lines, VIVO and Locket. Such statements also include any implied statements regarding the potential benefits to flow from the Phase II study, the rest of the LockeT studies, as well as any implied statement about the continued successful roll-out of LockeT. The Company's expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to the risk that Phases II and III will not achieve the outcomes that we expect; that members of the EP community and other doctors and hospitals will fail to recognize LockeT's value or for other reasons will prefer other methodologies and/or products, including the products of our current competitors as well as possible new and emerging competing products of which we are not yet aware; the risk that hospitals undergoing initial evaluations may not choose to continue using LockeT following such evaluation; risks that we will be unable to obtain the necessary financing to carry out our business goals, including to continue ongoing efforts to gather and publish clinical data and to build out LockeT as well as VIVO; risk that peer-reviewed journals or other journals may choose not to publish data submitted in connection with our products; risks that our business relationships with distribution partners and customers could be disrupted by armed conflicts and unrest in Israel and the Gaza strip and elsewhere, and/or changes in U.S. international relations and/or related geopolitical changes; and other, or disruptions to local and global economies; and the other risks and uncertainties attendant to our business included under the caption "Risk Factors" in the Company's Form 10-K and other SEC filings available at www.sec.gov. These additional risks and uncertainties include, but aren't limited to, risks that our cash needs will continue to exceed our liquidity, we will not be able to reach profitability unless we are able to achieve our product expansion and growth goals, our research and development and commercialization efforts may depend on entering into agreements with corporate collaborators, we have entered into joint marketing agreements with respect to our products, and may enter into additional joint marketing agreements, that will reduce our revenues from product sales, royalty agreements with respect to our LockeT device will reduce any future profits from this product, if we experience significant disruptions in our information technology systems, our business may be adversely affected, litigation and other legal proceedings may adversely affect our business, if we make acquisitions or divestitures, we could encounter difficulties that harm our business, failure to attract and retain sufficient qualified personnel could also impede our growth, failure to maintain effective internal controls could cause our investors to lose confidence in us and adversely affect the market price of our common stock, we have determined that our internal controls and disclosure controls were not effective as of December 31, 2023 and March 31, 2024, and as a result, without effective remediation of the material weaknesses that we have identified, we may not be able to accurately report our financial results or prevent fraud, our revenues may depend on our customers' receipt of adequate reimbursement from private insurers and government sponsored healthcare programs, we may be unable to compete successfully with companies in our highly competitive industry, many of whom have substantially greater resources than we do, our future operating results depend upon our ability to obtain components and finished product in sufficient quantities on commercially reasonable terms or according to schedules, prices, quality and volumes that are acceptable to us, and suppliers may fail to deliver components or finished product, or we may be unable to manage these components or product procurement effectively or obtain these components or products on such terms, if hospitals, physicians and patients do not accept our current and future products or if the market for indications for which any product candidate is approved is smaller than expected, we may be unable to generate significant revenue, if any, our medical device operations are subject to pervasive and continuing FDA regulatory requirements, our products may be subject to potential product liability risks as well as additional recalls, revocations or suspensions after receiving FDA or foreign approval or clearance, which could divert managerial and financial resources, harm our reputation, and adversely affect our business, changes in trade policies among the U.S. and other countries, in particular the imposition of new or higher tariffs, could place pressure on our average selling prices as our customers seek to offset the impact of increased tariffs on their own products, increased tariffs or the imposition of other barriers to international trade could have a material adverse effect on our revenues and operating results. The risks and uncertainties described above may be amplified by the COVID-19 pandemic, which has caused significant economic uncertainty, or other pandemics, disruptions to our ability to conduct business overseas, including to our supply chain, from the Ukraine war, the Israeli-Hamas armed conflict and other ongoing hostilities and instabilities in the Middle East and elsewhere, and ongoing volatility in the stock markets and the U.S. economy in general. In addition, market conditions that are outside our control could significantly how our stock is viewed by potential investors.

CONTACTS:

At the Company

David Jenkins
973-691-2000
IR@catheterprecision.com

# # #

SOURCE: Catheter Precision, Inc

View the original press release on accesswire.com

FAQ

What is the current status of Catheter Precision's LockeT-II Study?

Catheter Precision has enrolled 75 patients in its LockeT-II Study, which is expected to conclude in October 2024.

How many patients are planned for the Phase II LockeT study by Catheter Precision (VTAK)?

The Phase II LockeT study is planned to include up to 100 patients in a one-to-one randomized study comparing LockeT to manual compression.

What were the results of Catheter Precision's Phase I LockeT study completed in 2023?

The Phase I study completed in 2023 showed that LockeT works for its intended purpose and there were no safety events.

When did Catheter Precision (VTAK) begin the product roll-out for LockeT?

Catheter Precision began the product roll-out for LockeT in the first half of 2024.